Cortet, B. et al. (2021): Non-Inferiority of a Single Injection of Sodium Hyaluronate Plus Sorbitol to Hylan G-F20: A 6-Month Randomized Controlled Trial. In Advances in Therapy 38 (5), pp. 2271–2283. DOI: 10.1007/s12325-021-01648-3
Cucurnia, I. et al. (2021): Patient-reported outcomes of intra-articular hyaluronic acid for osteoarthritis of the knee: a prospective and multicentric case series. In Musculoskeletal surgery 2022 Sep;106(3):303-310. Epub 2021 Jan 24. DOI: 10.1007/s12306-021-00698-8
Dott. Moretti, L. et al. (2021). Outcome clinici post infilitrazione one shot di acido ialuronico ad alto peso molecolare con aggiunta di sorbitolo in pazienti con hip diseases, follow up 6 mesi. Poster SIOT, 13-14 September 2021
Migliore A, et al. (2014): Duration of symptom relief after intra-articular injection of hyaluronic acid combined with sorbitol (anti-ox-vs) in symptomatic hip osteoarthritis. Int J Immunopathol Pharmacol 2014;27:245-252. DOI: 10.1177/039463201402700211
Radenne, F. (2014). Pain relief, functional recovery and associated medical treatments reduction in large-scale population with osteoarthritis receiving injections of viscosupplement incorporating high concentration of sorbitol. Osteoarthritis and Cartilage, Volume 22, Supplement, S407, April 2014. DOI: 10.1016/j.joca.2014.02.764
Gavard, S. An innovative hyaluronic acid product for viscosupplementation in patients with osteoarthritis. Osteoarthritis and Cartilage, Volume 21, Supplement , S302-S303, April 2013. DOI:https://doi.org/10.1016/j.joca.2013.02.631
Mongkhon, J.-M., et al. (2014): Sorbitol-modified hyaluronic acid reduces oxidative stress, apoptosis and mediators of inflammation and catabolism in human osteoarthritic chondrocytes. Inflamm Res. 2014 Aug;63(8):691-701. Epub 2014 May 25. DOI: 10.1007/s00011-014-0742-4
Heisel, J., et al. (2012): Hyaluronic acid with sorbitol-efficacy and tolerability of intra-articular treatment for osteoarthritis of the knee. In Orthopädie und unfallchirurgie zeitschrift 1, pp. 1–7
Post Market Surveillance (PMS) Data on file
PMCF2-4mL – “An efficacy and safety 6-months study of SYNOLIS VA 80/160 and SYNOLIS VA 40/80 in the treatment of symptomatic knee osteoarthritis” (Interim Clinical Study Report dated 5 August 2021)
IFU
